AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31469675 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 63
Study 26297091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditto intervention (n = 35)
Number of subjects: 75
Study 26297091 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (n = 40)
Number of subjects: 75
Study 24338229 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga breathing exercises for 8 weeks
Number of subjects: 120
Study 22552505 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term antibiotic prophylaxis (single dose)
Number of subjects: 527
Study 22552505 — intervention group
Group type: COMPARATOR
Intervention: Long-term antibiotic prophylaxis (multiple dose)
Number of subjects: 527
Study 19414832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement and medical treatment (64 patients)
Number of subjects: 140
Study 19414832 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (76 patients)
Number of subjects: 140
Study 19414832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 140
Study 19414832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement with medical treatment
Number of subjects: 140
Study 19414832 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 140
Study 18089250 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem threat with false failure feedback and exposure to thin models
Number of subjects: 94
Study 18089250 — intervention group
Group type: COMPARATOR
Intervention: Self-esteem threat with false success feedback and exposure to thin models
Number of subjects: 94
Study 14971623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainly computer-guided self-exposure therapy (FearFighter)
Number of subjects: 93
Study 14971623 — intervention group
Group type: EXPERIMENTAL
Intervention: Entirely clinician-guided self-exposure therapy
Number of subjects: 93
Study 14971623 — intervention group
Group type: COMPARATOR
Intervention: Self-relaxation (placebo)
Number of subjects: 93
Study 11813272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 213
Study 11813272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS) subscales
Number of subjects: 213
Study 9805328 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunted hydrocephalus group
Number of subjects: 157
Study 9805328 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrested hydrocephalus group
Number of subjects: 157
Study 9805328 — intervention group
Group type: COMPARATOR
Intervention: No hydrocephalus group
Number of subjects: 157
Study 7924466 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (Naughton modified protocol, holding on handrails permitted)
Number of subjects: 40
Study 7924466 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise (10 W/min)
Number of subjects: 40
Study 7924466 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 40
Study 7924466 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise
Number of subjects: 40
Study 2695009 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of immobilization
Number of subjects: 85
Study 2695009 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks of immobilization
Number of subjects: 85
Study 331760 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-influenza lactoglobulin
Number of subjects: 6361
Study 31465720 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 165
Study 31465720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 165
Study 31465720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 29424935 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended hours haemodialysis (≥24 h/week)
Number of subjects: 200
Study 29424935 — intervention group
Group type: COMPARATOR
Intervention: Standard hours haemodialysis (target 12‐15 h)
Number of subjects: 200
Study 27647820 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis brownie (6.9% THC)
Number of subjects: 0
Study 27647820 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoked cannabis
Number of subjects: 0
Study 27647820 — intervention group
Group type: COMPARATOR
Intervention: Oral cannabis
Number of subjects: 0
Study 27647820 — intervention group
Group type: COMPARATOR
Intervention: Inhaled routes (smoked or vaporized)
Number of subjects: 0
Study 26052057 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nailing
Number of subjects: 54
Study 26052057 — intervention group
Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty
Number of subjects: 54
Study 24855129 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training for clinicians
Number of subjects: 134
Study 24855129 — intervention group
Group type: COMPARATOR
Intervention: IPS-only teams (control)
Number of subjects: 134
Study 21830318 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 18
Study 21830318 — intervention group
Group type: COMPARATOR
Intervention: Pressure Trigger
Number of subjects: 18
Study 21830318 — intervention group
Group type: COMPARATOR
Intervention: Flow Trigger
Number of subjects: 18
Study 21830318 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 18
Study 19641971 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 0
Study 17803059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vazkor 10 mg tablet (test preparation)
Number of subjects: 18
Study 17803059 — intervention group
Group type: COMPARATOR
Intervention: 10 mg tablet of the originator product (reference preparation)
Number of subjects: 18
Study 17803059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference preparations
Number of subjects: 18
Study 15217803 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta carotene, 100 microg selenium, and 20 mg zinc)
Number of subjects: 1162
Study 15217803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study 15217803 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 1162
Study 11427639 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg)
Number of subjects: 60
Study 11427639 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg)
Number of subjects: 60
Study 11427639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamins E and C
Number of subjects: 60
Study 11427639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9723560 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis with methacholine hyperresponsiveness
Number of subjects: 40
Study 9723560 — intervention group
Group type: COMPARATOR
Intervention: Allergic rhinitis with normal methacholine responsiveness
Number of subjects: 40
Study 9723560 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 7981777 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.1 mg/kg/day (n = 10)
Number of subjects: 20
Study 7981777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 3057036 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem (360 mg/day)
Number of subjects: 21
Study 3057036 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (120 mg/day)
Number of subjects: 21
Study 3057036 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem and nifedipine
Number of subjects: 21
Study 488802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation within 24-72 hours
Number of subjects: 286
Study 488802 — intervention group
Group type: COMPARATOR
Intervention: Bed rest for the first seven days
Number of subjects: 286
Study 488802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation
Number of subjects: 286
Study 30460734 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 29
Study 30460734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25193946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 I.U.)
Number of subjects: 100
Study 25193946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23624215 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (420mg daily)
Number of subjects: 30
Study 23624215 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (40mg/kg/day) + Silymarin (420mg daily)
Number of subjects: 30
Study 21853784 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapalabhati
Number of subjects: 30
Study 21853784 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath awareness
Number of subjects: 30
Study 21853784 — intervention group
Group type: COMPARATOR
Intervention: Control (nonyoga practitioners)
Number of subjects: 30
Study 19623172 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) withdrawal
Number of subjects: 127
Study 19623172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosalicylates
Number of subjects: 127
Study 17371601 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Directed Therapy (GDT)
Number of subjects: 12
Study 17371601 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 15550792 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP-treated group (n = 13, 0.05 microg/kg/min of synthetic human alpha-ANP administered postoperatively)
Number of subjects: 26
Study 11075311 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin (PBCD) 20 mg
Number of subjects: 48
Study 11075311 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (Feldene) 20 mg
Number of subjects: 48
Study 9108811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 64
Study 9108811 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 64
Study 8211041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bezafibrate 400 mg per day for 56 days
Number of subjects: 31
Study 8211041 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 56 days
Number of subjects: 31
Study 3518049 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 14
Study 3518049 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan
Number of subjects: 14
Study 30466131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate therapy (up to 4 times daily for 14 days)
Number of subjects: 155
Study 29345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 200
Study 29345158 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐PUFA
Number of subjects: 200
Study 29345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and LC‐PUFA
Number of subjects: 200
Study 29345158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26945497 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus after 2 months of placebo in polysensitized patients.
Number of subjects: 43
Study 26945497 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus after 2 months of placebo in monosensitized patients.
Number of subjects: 43
Study 26945497 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus in both groups.
Number of subjects: 43
Study 26945497 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus in polysensitized patients.
Number of subjects: 43
Study 25927907 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation added to standard care
Number of subjects: 90
Study 25927907 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 90
Study 23151221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (single RDA of vitamins B1, B2, B6, B12, niacin, C, E, and folic acid)
Number of subjects: 0
Study 23151221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23151221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0
Study 20303236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free milk (400 mL daily for mild, 600 mL for moderate, 800 mL for severe constipation)
Number of subjects: 30
Study 20303236 — intervention group
Group type: COMPARATOR
Intervention: Whole milk (400 mL for 3 days)
Number of subjects: 30
Study 17953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradigm Real-Time System
Number of subjects: 0
Study 16301159 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous Ca(OH)2 slurry mixed with 2% chlorhexidine (CHX)
Number of subjects: 40
Study 16301159 — intervention group
Group type: COMPARATOR
Intervention: Aqueous Ca(OH)2 slurry alone
Number of subjects: 40
Study 12085028 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (injection of epinephrine, mechanical removal of clot, coagulation)
Number of subjects: 56
Study 9527083 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 17)
Number of subjects: 36
Study 9527083 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 36
Study 8591078 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM chemotherapy (5-FU, doxorubicin, mitomycin C) for 1 year (6 cycles)
Number of subjects: 193
Study 8591078 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (observation only)
Number of subjects: 193
Study 8591078 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM chemotherapy
Number of subjects: 193
Study 8591078 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative surgical resection
Number of subjects: 193
Study 1977760 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms CV (iv)
Number of subjects: 27
Study 1977760 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms CV (iv)
Number of subjects: 27
Study 1977760 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms CV (iv)
Number of subjects: 27
Study 1977760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram CV (iv)
Number of subjects: 27
Study 1977760 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms CV (orally)
Number of subjects: 27
Study 103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg i.v. and 0.5 mg s.c.)
Number of subjects: 0
Study 103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion (0.3 mmol/kg.105 min)
Number of subjects: 0
Study 103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion (0.12 mmol/kg.45 min)
Number of subjects: 0
Study 30551730 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Cryotherapy (WBC) - 3‐min at ‐40°C, wind speed of 2.3 m s‐1
Number of subjects: 22
Study 30551730 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (Control)
Number of subjects: 22
Study 28129548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dru yoga intervention (n=16): one-hour session each week for 4 weeks and a 20-minute DVD for home practice.
Number of subjects: 32
Study 28129548 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16): no intervention.
Number of subjects: 32
Study 25841214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost improved cooking stoves
Number of subjects: 0
Study 25841214 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional cooking methods)
Number of subjects: 0
Study 23434613 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention using motivational interviewing strategies
Number of subjects: 0
Study 23434613 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 0
Study 21385361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedalling daily for up to ten minutes, for up to ten working days (experimental group)
Number of subjects: 24
Study 21385361 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation (all participants)
Number of subjects: 24
Study 21385361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedalling (experimental group)
Number of subjects: 24
Study 20032909 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Index for physiotherapy (PSI-PD)
Number of subjects: 81
Study 17341317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 5 mg after formoterol treatment
Number of subjects: 22
Study 17341317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 mug after formoterol treatment
Number of subjects: 22
Study 17341317 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol 5 mg after placebo treatment
Number of subjects: 22
Study 17341317 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 40 mug after placebo treatment
Number of subjects: 22
Study 14987299 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated BCG (0.1 mL injection once a week for 4 weeks)
Number of subjects: 31
Study 14987299 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 31
Study 11251566 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of terbinafine (62.5 mg daily for <20 kg, 125 mg daily for 20-40 kg, 250 mg daily for >40 kg)
Number of subjects: 210
Study 11251566 — intervention group
Group type: COMPARATOR
Intervention: 8 weeks of griseofulvin (10 mg/kg daily)
Number of subjects: 210
Study 11251566 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of terbinafine in patients with Trichophyton infections weighing >20 kg
Number of subjects: 210
Study 9256560 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance ratings by clients or therapists in outpatient sample
Number of subjects: 0
Study 9256560 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists ratings of the alliance in the aftercare sample
Number of subjects: 0
Study 9256560 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic alliance ratings by aftercare clients
Number of subjects: 0
Study 8297488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (DuoDERM CGF)
Number of subjects: 70
Study 8297488 — intervention group
Group type: COMPARATOR
Intervention: Moist gauze dressings
Number of subjects: 70
Study 3440634 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (3 to 12 mg daily for 12 weeks)
Number of subjects: 188
Study 3440634 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (with and without piretanide) and amiloride in combination with hydrochlorothiazide
Number of subjects: 188
Study 3440634 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 188
Study 29168570 — intervention group
Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (Phl‐SCIT)
Number of subjects: 56
Study 29168570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28654972 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pill bottles combined with lottery incentives and social support for medication adherence (1003 patients)
Number of subjects: 1509
Study 28654972 — intervention group
Group type: COMPARATOR
Intervention: Usual care (506 patients)
Number of subjects: 1509
Study 25893563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (DH)
Number of subjects: 10
Study 25893563 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EH)
Number of subjects: 10
Study 23061492 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus telephone support (UC+I)
Number of subjects: 405
Study 23061492 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 405
Study 21621993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP) for 6 weeks
Number of subjects: 30
Study 21621993 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (15% of MIP) for 6 weeks
Number of subjects: 30
Study 18959604 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (n = 125)
Number of subjects: 271
Study 18959604 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (n = 146)
Number of subjects: 271
Study 16822113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 62
Study 16822113 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus applied relaxation (EXP = AR)
Number of subjects: 62
Study 16822113 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WAIT)
Number of subjects: 62
Study 12659241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculation followed by 7 days of abstinence
Number of subjects: 28
Study 12659241 — intervention group
Group type: COMPARATOR
Intervention: Continuous abstinence after ejaculation
Number of subjects: 28
Study 10194085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis (DTaP) vaccine
Number of subjects: 2187
Study 10194085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lederle whole‐cell component diphtheria and tetanus toxoids and pertussis (DTP) vaccine
Number of subjects: 2187
Study 10194085 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria and tetanus toxoids (DT) vaccine
Number of subjects: 2187
Study 8546476 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride 3 mg/body administered by intravenous drip before chemotherapy (group A)
Number of subjects: 22
Study 8546476 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride 3 mg/body administered by intravenous drip before chemotherapy (group B)
Number of subjects: 22
Study 1858704 — intervention group
Group type: EXPERIMENTAL
Intervention: L-amino acid diets providing 40 mg leucine.kg-1.d-1
Number of subjects: 11
Study 1858704 — intervention group
Group type: EXPERIMENTAL
Intervention: L-amino acid diets providing 15 mg leucine.kg-1.d-1
Number of subjects: 11
Study 1858704 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable amounts of valine and isoleucine
Number of subjects: 11
Study 6137857 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 16
Study 6137857 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 16